ライフサイエンスコーパス: sideroblast

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 lated with unilineage dysplasia without ring sideroblasts.

2 r a diagnosis of refractory anemia with ring sideroblasts.

3 scovered in a distinct form of MDS with ring sideroblasts.

4 f myelodysplastic syndrome (MDS) with ringed sideroblasts.

5 O) therapy for refractory anemia with ringed sideroblasts.

6 d dysplasia and 15% or more bone marrow ring sideroblasts.

7 ts with myeloid neoplasm and 1% or more ring sideroblasts.

8 ry anemia (7), refractory anemia with ringed sideroblasts (5), refractory anemia with excess blasts (

9 s blasts (35), refractory anemia with ringed sideroblasts (9), and refractory anemia with excess blas

10 S/MPD-U entity refractory anemia with ringed sideroblasts and thrombocytosis (RARS-T).

11 refractory anemia (RA); 5 had RA with ringed sideroblasts; and 2 had RA with excess blasts.

12 and >500 IU/L); presence of 15% or more ring sideroblasts; and presence of SF3B1 mutations.

13 Ring sideroblasts are found also in other MDS subtypes, such

14 eloid leukemia, MDS/MPN-Unclassifiable, ring sideroblasts associated with marked thrombocytosis, and

15 n(s) in our cohort of MDS patients with ring sideroblasts can arise from CD34(+)CD38(-)CD45RA(-)CD90(

16 e of RARS/RARS-T is the presence of abnormal sideroblasts characterized by iron overload in the mitoc

17 risk (refractory anemia [RA]/RA with ringed sideroblasts/chronic myelomonocytic leukemia with < 5% b

18 define a subgroup of patients with the ring sideroblast form of MDS and a favorable prognosis.

19 eloid precursors, excess iron stores, ringed sideroblasts, iron incorporation in plasma cells, and va

20 Among other patients with ring sideroblasts, lower prevalence of SF3B1 mutations and hi

21 ents with myelodysplastic syndrome with ring sideroblasts (MDS-RS).

22 quent in myelodysplastic syndromes with ring sideroblasts (MDS-RS; approximately 75% incidence) and S

23 efractory anemia/refractory anemia with ring sideroblasts [RA/RARS]) have low levels of NF-kappaB act

24 ed in 60%-80% of refractory anemia with ring sideroblasts (RARS) and RARS associated with thrombocyto

25 cantly between refractory anemia with ringed sideroblasts (RARS) and refractory anemia with multiline

26 Refractory anemia with ring sideroblasts (RARS) is a myelodysplastic syndrome (MDS)

27 refractory anemia (RA), 3 had RA with ringed sideroblasts (RARS), 5 had RA with excess blasts (RAEB),

28 penia with multilineage dysplasia and ringed sideroblasts (RCMD-RS) and UPD4q24, and five patients (r

29 topenia with multilineage dysplasia and ring sideroblasts (RCMD-RS).

30 nemia with multilineage dysplasia and ringed sideroblasts (RCMD/RS) with regard to therapeutic respon

31 actory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refr

32 he presence of >/= 15% bone marrow (BM) ring sideroblasts (RS) and < 5% blasts is required for a diag

33 s (MDSs), especially in the presence of ring sideroblasts (RSs).

34 atients with the refractory anemia with ring sideroblasts subtype of myelodysplastic syndrome (MDS) h

35 B1 mutation with refractory anemia with ring sideroblasts, TET2/SRSF2 comutation with chronic myelomo

36 In contrast, we found typical ring sideroblasts that accumulated iron mostly in mitochondri

37 HSCs differentiated into characteristic ring sideroblasts, the hallmark of MDS-RS.

38 ions are prevalent in low-risk MDS with ring sideroblasts, whereas U2AF1 and SRSF2 mutations are freq

39 uency among conditions characterized by ring sideroblasts, which is consistent with a causal relation

40 Conversely, MDS with ring sideroblasts with nonmutated SF3B1 segregated in differe

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。